Myeloproliferative neoplasm laboratory findings: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
Shyam Patel (talk | contribs) |
||
| Line 20: | Line 20: | ||
:*Increased [[granulocyte]]s of all types | :*Increased [[granulocyte]]s of all types | ||
:*Increased [[basophil]]s and [[eosinophil]]s | :*Increased [[basophil]]s and [[eosinophil]]s | ||
:*[[Thrombocytopenia]] | :*[[Thrombocytopenia]] or thrombocythemia | ||
:*[[Anemia]] | :*[[Anemia]] or [[polycythemia]] | ||
*Blood chemistry | *Blood chemistry | ||
:*The following blood levels may be elevated: | :*The following blood levels may be elevated: | ||
| Line 32: | Line 31: | ||
::*[[Aspartate transaminase]] (AST) | ::*[[Aspartate transaminase]] (AST) | ||
::*[[Uric acid]] | ::*[[Uric acid]] | ||
*Bleeding and clotting | *Bleeding and clotting factors | ||
:*The following blood | :*The following blood parameters may be elevated: | ||
::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR) | ::*[[Prothrombin time]] (PT) or [[international normalized ratio]] (INR) | ||
::*[[Partial thromboplastin time]] (PTT) | ::*[[Partial thromboplastin time]] (PTT) | ||
*[[ | ::*[[D-dimer]] | ||
*[[Flow cytometry]] | *[[Flow cytometry]] | ||
:* Flow cytometry helps determine the type of cells that are present | :* Flow cytometry helps determine the type of cells that are present. | ||
*[[Cytogenetics]] | *[[Cytogenetics]] or [[karyotyping]] | ||
:*Chromosome changes that may occur in some people with leukemia include: | :*Chromosome changes that may occur in some people with leukemia include: | ||
::*[[Translocations]] | ::*[[Translocations]] | ||
::*Inversions | ::*[[Inversions]] | ||
::* | ::*Loss or gain of a chromosome number | ||
*[[Fluorescent in situ hybridization]] (FISH) | *[[Fluorescent in situ hybridization]] (FISH) | ||
:*Similar to cytogenetics, but more specific | :*Similar to cytogenetics, but more specific for particular chromosomal translocations | ||
*Polymerase chain reaction | *Polymerase chain reaction | ||
:*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | :*Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample. | ||
Revision as of 21:42, 21 June 2018
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm laboratory findings On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm laboratory findings |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.
Laboratory Findings
Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]
- Increased granulocytes of all types
- Increased basophils and eosinophils
- Thrombocytopenia or thrombocythemia
- Anemia or polycythemia
- Blood chemistry
- The following blood levels may be elevated:
- Blood urea nitrogen (BUN)
- Creatinine
- Phosphate
- Lactate dehydrogenase (LDH)
- Alanine aminotransferase (ALT)
- Aspartate transaminase (AST)
- Uric acid
- Bleeding and clotting factors
- The following blood parameters may be elevated:
- Prothrombin time (PT) or international normalized ratio (INR)
- Partial thromboplastin time (PTT)
- D-dimer
- Flow cytometry helps determine the type of cells that are present.
- Chromosome changes that may occur in some people with leukemia include:
- Translocations
- Inversions
- Loss or gain of a chromosome number
- Similar to cytogenetics, but more specific for particular chromosomal translocations
- Polymerase chain reaction
- Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
- Neutrophil alkaline phosphatase level
- Vitamin B12 (or B12 binding capacity)
Gallery
-
![Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]](/images/b/ba/MPN-FISH.jpg)
Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]
![Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]](/index.php/File:MPN-FISH.jpg)
References
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
- ↑ James W. Vardiman (2009). "Chronic myelogenous leukemia, BCR-ABL1+". American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter
|month=ignored (help) - ↑ Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). "Evaluation of the WHO criteria for the classification of patients with mastocytosis". Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
- ↑ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
- ↑ O'Brien, S. (2004). "Chronic Myelogenous Leukemia and Myeloproliferative Disease". Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
- ↑ Murakami J, Shimizu Y (2013). "Hepatic manifestations in hematological disorders". Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
- ↑ Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review". Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.